Orphazyme stock plummets following bad news from CHMP
The Danish biotech company is being punished on the stock exchange after the CHMP, an EMA expert committee, had a negative reaction to the company’s oral presentation on Wednesday.
by marketwire, translated by daniel pedersen
Orphazyme stock is down by 34 percent, dropping to DKK 9.2 (USD 1.4) per share.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Orphazyme predicts EU rejection after meeting with CHMP
For subscribers
Leo Pharma poaches Orphazyme CEO
For subscribers
